Ocumension Therapeutics
01477
Company Profile
Business description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Contact
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
SuzhouJiangsu
CHNT: +86 2161493800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
489
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,853.70 | 60.20 | -0.76% |
| CAC 40 | 7,104.80 | 21.22 | -0.30% |
| DAX 40 | 20,374.10 | 188.63 | -0.92% |
| Dow JONES (US) | 40,185.60 | 591.94 | 1.50% |
| FTSE 100 | 7,964.18 | 50.93 | 0.64% |
| HKSE | 20,914.69 | 232.91 | 1.13% |
| NASDAQ | 16,670.64 | 283.33 | 1.73% |
| Nikkei 225 | 33,585.58 | 1,023.42 | -2.96% |
| NZX 50 Index | 12,019.13 | 182.30 | -1.49% |
| S&P 500 | 5,352.67 | 84.62 | 1.61% |
| S&P/ASX 200 | 7,646.50 | 63.10 | -0.82% |
| SSE Composite Index | 3,238.23 | 14.59 | 0.45% |